1 2 3

Human ASXL1 Deficiency Causes Epigenetic Dysfunction, Combined Immunodeficiency and EBV–Associated Hodgkin Lymphoma

4 Maggie P Fu^{1*}, Mehul Sharma^{2*}, Sarah M Merrill³, Pariya Yousefi², Ryan Tan², Bhavi P 5 Modi², Kate Del Bel², Rebecca J Devell⁴, Jacob Rozmus⁴, Wingfield Rehmus^{2,5}, Kyla J Hildebrand², Elliot James², Géraldine Blanchard-Rohner^{2,6}, Susan Lin², Kevin E 6 7 Shopsowitz^{2,7}, Audi Setiadi⁷, Jefferson Terry⁷, Anna F Lee⁷, Britt I Drögemöller^{8,9}, Allison Matthews^{1,10}, Maja Tarailo-Graovac^{1,11}, Laura Sauvé^{2,12}, Hana Mitchell², Julie S 8 Prendiville^{2,5}, Julie L MacIsaac^{1,13}, Kristy Dever^{1,13}, David T S Lin¹, Mandy Meijer^{1,13}, 9 Colin J D Ross⁹, Simon R M Dobson^{2,12}, Suzanne M Vercauteren⁷, Wyeth W 10 Wasserman¹, Clara D M van Karnebeek^{2,14,15}, Margaret L McKinnon^{2,16}, Michael S 11 Kobor^{1,13#}, Stuart E Turvey^{2#}, Catherine M Biggs^{2#} 12 13 14 ¹British Columbia Children's Hospital, Centre for Molecular Medicine and Therapeutics, 15 Department of Medical Genetics. University of British Columbia, Vancouver, BC. 16 Canada. ²Department of Pediatrics, British Columbia Children's Hospital, The University of British 17 18 Columbia, Vancouver, BC, Canada. 19 ³Department of Psychiatry and Human Behavior, The Warren Alpert Medical School at 20 Brown University, Providence, RI, USA. ⁴Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, British 21 22 Columbia Children's Hospital, University of British Columbia, Vancouver, BC, Canada. 23 ⁵Divisions of Pediatric Dermatology, Department of Pediatrics, British Columbia 24 Children's Hospital, University of British Columbia, Vancouver, BC, Canada. 25 ⁶Unit of Immunology and Vaccinology, Division of General Pediatrics, Dept. of Woman, Child, and Adolescent Medicine, Geneva University Hospitals and Faculty of Medicine, 26 27 University of Geneva, Geneva, Switzerland. 28 ⁷Department of Pathology and Laboratory Medicine, University of British Columbia, 29 Vancouver, BC, Canada, 30 ⁸Department of Biochemistry and Medical Genetics, Rady Faculty of Health Sciences, 31 University of Manitoba, Winnipeg, MB, Canada. 32 ⁹Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, 33 Canada. ¹⁰Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada. 34 ¹¹Alberta Children's Hospital Research Institute, Department of Biochemistry and 35 36 Molecular Biology and Department of Medical Genetics, Cumming School of Medicine, 37 University of Calgary, Calgary, Alberta, Canada. 38 ¹²Pediatric Infectious Diseases, Department of Pediatrics, British Columbia Children's Hospital, University of British Columbia, Vancouver, BC, Canada. 39 40 ¹³Edwin S.H. Leong Healthy Aging Program, University of British Columbia, Vancouver, 41 Canada. 42 ¹⁴Departments of Pediatrics and Human Genetics, Emma Center for Personalized Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands. 43

- ¹⁵Centre for Molecular Medicine and Therapeutics, BC Children's Hospital Research
- 45 Institute, Vancouver, Canada.
- ¹⁶Department of Medical Genetics, University of British Columbia, Vancouver, Canada.
- 47 48 49 *These authors contributed equally. [#]These authors contributed equally. 50 51 52 53 **Correspondence to:** Catherine M. Biggs, MD, MSc 54 BC Children's Hospital, 55 4480 Oak St, Vancouver, BC, V5Z 4H4, Canada 56 57 Phone: 604-875-2118 ext 2 58 Email: cbiggs@bcchr.ca 59 60 **Word count**: <u>4068</u> 61 62

Fu, Sharma et al.

63 ABSTRACT

64 Inborn errors of immunity (IEI) are a group of disorders caused by deleterious variants 65 in immune-related genes, including some that function as epigenetic regulators. 66 Additional sex combs-like 1 (ASXL1) is an epigenetic modifier that has not previously 67 been linked to an IEI. Somatic ASXL1 variants are found in clonal hematopoiesis and 68 hematologic neoplasms, while heterozygous germline variants cause Bohring–Opitz 69 syndrome. We present a new IEI caused by biallelic germline variants in ASXL1. The 70 patient had a complex and unusual history of disease progression notable for persistent 71 cutaneous vaccine-strain rubella granulomas initially manifesting in early childhood, 72 chronic macrocytosis and mild bone marrow cellular hypoplasia, and Epstein Barr virus-73 associated Hodgkin lymphoma in adolescence. Detailed immunophenotyping revealed 74 progressive loss of B-cells, hypogammaglobinemia, and T-cell lymphopenia with severe 75 skewing toward a memory phenotype and elevated expression of T-cell exhaustion and 76 senescence markers. Molecular investigations confirmed ASXL1 protein deficiency in 77 the patient's T-cells and fibroblasts. The T-cells exhibited marked loss of DNA 78 methylation, increased epigenetic aging, and CD8 T-cell dysfunction. These aberrations 79 were ameliorated by lentivirus-mediated transduction with wild-type ASXL1, confirming 80 the pathogenicity of ASXL1 variants. This study defines a novel human IEI caused by 81 ASXL1 deficiency, a diagnosis that should be considered in individuals with chronic viral 82 infections, virus-associated hematologic malignancies, and combined immunodeficiency. Furthermore, our findings provide fresh insights into the mechanisms 83 84 underlying the roles of human ASXL1 in T-cell function as well as in the development 85 and maintenance of lymphomas.

86 INTRODUCTION

87 Monogenic inborn errors of immunity (IEIs) are a group of more than 480 rare diseases 88 caused by deleterious germline variants in immune-related genes.¹ Some of these IEI 89 disease-causing variants occur in genes encoding epigenetic regulators that modify 90 steady-state gene expression and cellular phenotype, such as DNMT3A and TET2.^{2,3} 91 These alterations in epigenetic regulation disrupt hematopoiesis and cellular 92 differentiation pathways that are important for immune function,^{4,5} giving rise to 93 inflammation, lymphoproliferation, and increased susceptibility to infections and 94 cancer.6,7

Hematologic malignancies account for the majority of cancers in IEIs and are mainly of 95 96 lymphoid origin, however, myeloid leukemias and myelodysplastic syndromes (MDS) also occur.⁶ Impaired cell-mediated immunosurveillance, chronic viral infections, and 97 98 inflammation contribute to the increased risk and early onset of cancers observed in 99 IEIs.^{8,9} Furthermore, the same mechanisms underlying immunodeficiency in certain IEIs 100 may also promote oncodenesis in a cell-intrinsic manner, such as DNA repair or 101 epigenetic defects, causing genomic instability.⁹ Somatic variants in IEI-associated 102 genes are also observed in hematologic malignancies, further supporting their oncogenic role.¹⁰ Indeed, acquired variants in the epigenetic regulatory genes <u>DNMT3A</u>, 103 104 TET2, and ASXL1 (DTA mutations) are common in age-related clonal hematopoiesis and myeloid neoplasms.^{11,12,13,14} ASXL1 (MIM #612990) is the least characterized of the 105 106 three DTA genes, and unlike DNMT3A and TET2 has not previously been linked with 107 immunodeficiency in humans.

ASXL1 comprises part of the Polycomb repressive deubiquitinase (PR-DUB) complex,¹⁵
which along with Polycomb repressor complexes 1 and 2 (PRC1/2) represses target
genes by modifying chromatin. In embryonic development, establishment of histone
H2A lysine 119 monoubiquitination (H2AK119ub1) by PRC1 is crucial for the
recruitment of PRC2 and corresponding transcriptional repression, and plays a key role
in establishing chromatin bivalency whereby histone modifications associated with
transcriptional activation or repression co-occur.^{16,17} The PR-DUB complex removes

- 115 H2AK119ub1 at later developmental stages to maintain transcriptional
- 116 regulation.^{16,17,18,19}
- 117 In keeping with the critical role of PR-DUB in development, de novo heterozygous loss-118 of-function (LoF) ASXL1 variants cause the neurodevelopmental disorder Bohring–Opitz 119 Syndrome (BOS), characterized by severe developmental delay, microcephaly, failure to thrive, and distinct facial features.²⁰ While Asx/1-null mice recapitulate BOS 120 121 phenotypes, heterozygous germline deletion and hematopoietic-specific Asx/1 deletion lead to MDS-like features.^{21,22} Mechanistic studies of BOS and ASXL1-associated 122 123 hematologic malignancies implicate ASXL1 in differential DNA methylation patterns and altered epigenetic age.^{23,24,25,26} Further, conditional knock-in of an Asx/1 variant 124 125 associated with clonal hematopoiesis revealed a phenotype of impaired T-cell 126 development, function and exhaustion that drove tumor progression in mice.^{27,28,29} 127 Here, we report the first patient with an IEI due to biallelic germline variants in ASXL1 128 causing ASXL1 deficiency presenting with combined immunodeficiency complicated by 129 vaccine-strain rubella virus granulomas and Epstein-Barr virus (EBV)-associated 130 Hodgkin lymphoma. We characterize the patient's clinical phenotype and treatment 131 course, and provide a mechanistic study of the epigenetic and immunological impact of 132 autosomal recessive ASXL1 deficiency. We anticipate that this discovery will empower 133 the diagnosis and management of additional patients with ASXL1 deficiency.

134 METHODS

135 **Participants and consent**

136 Peripheral blood samples were collected from the index patient and patient's parents 137 and sibling, as well as three unrelated healthy individuals at the BC Children's Hospital 138 Research Institute. Similarly, skin biopsies were collected from the patient and six 139 healthy individuals. All participants from whom we collected biological samples and/or 140 their parents/quardians provided written informed consent for sample collection, 141 sequencing, data analysis, and the publication of findings and photographs. Data from 142 additional samples were obtained from publicly available databases, as outlined below. 143 The research protocols were approved by the University of British Columbia Clinical 144 Research Ethics Board (H15-00641).

145 Identification of candidate variant

146 Genomic DNA was isolated from peripheral blood using standard procedures and 147 exome/genome sequencing was performed on the Illumina HiSeq platform (Macrogen, 148 Seoul, South Korea). Sequencing data were analyzed using an updated version of our 149 in-house, open-source, semi-automated bioinformatics pipeline as described 150 previously.^{30,31} Trio whole-exome sequencing (trio-WES) was performed on genomic 151 DNA from the patient and both parents. Compound heterozygous ASXL1 variants were 152 considered the top candidates of interest. Additional information on candidate gene 153 selection is available in the **Supplementary Methods**. Whole-genome sequencing 154 (WGS) was then performed to scan for potential somatic mosaic variants and to exclude 155 variants in noncoding regions. Compound heterozygous ASXL1 variants still emerged 156 as the variants of highest significance and were further verified by sequencing 157 (Supplementary Methods).

158 Generation and maintenance of patient's primary T-cells and fibroblasts

- 159 For generation of T-cell blasts, T-cells were isolated from peripheral blood mononuclear
- 160 cells (PBMCs) (EasySep[™] Human T-Cell Isolation Kit, Cat # 17951; Stemcell,
- 161 Vancouver, BC, Canada) and activated for 12 days (**Supplementary Methods**).
- 162 To generate fibroblasts, a skin biopsy was obtained, manually cut into smaller pieces,
- 163 and placed in separate wells of a 6-well plate in complete DMEM (GE Healthcare,
- 164 Chicago, IL, USA) until formation of a confluent fibroblast monolayer (**Supplementary**
- 165 Methods).

166 Stable WT ASXL1 expression in expanded patient-derived T-cells

- 167 Stable wild-type (WT) ASXL1 expression was achieved by infection of expanded
- 168 patient-derived T-cells with lentiviral particles as described previously,^{32,33} and
- 169 expanded cells were used for downstream DNA methylation and intracellular flow
- 170 cytometric analyses (Supplementary Methods).

171 **DNA methylation array**

- 172 Blood and buccal swabs were collected from the index patient, and genomic DNA was
- 173 extracted from whole blood (WB), PBMCs, buccal cells, and cultured T-cells. Aliquots of
- 174 160 ng of extracted DNA (750 ng) subjected to bisulfite conversion (EZ-96 DNA
- 175 Methylation kit; Zymo Research, Irvine, CA, USA) were assayed. DNA extracted from
- 176 primary tissues and T-cells was assayed using Infinium HumanMethylationEPIC
- 177 BeadChip (EPIC) and HumanMethylationEPICv2 BeadChip arrays (Illumina, San Diego,
- 178 CA, USA), respectively. Two patient PBMC samples were prepared and assayed as
- technical replicates on the EPIC arrays. (**Supplementary Methods**).

180 Sample selection for pediatric population reference set

- 181 To establish a pediatric population reference set, publicly available DNAm microarray
- 182 data on blood and buccal samples were downloaded from the Gene Expression
- 183 Omnibus (GEO) database, including both EPIC arrays and their predecessors, the
- 184 Illumina Infinium HumanMethylation450 BeadChip (450k) arrays. We filtered for healthy

- 185 control (HC) samples with the cohorts and sample selection outlined in the
- 186 Supplementary Methods. The cohorts and demographics are described in
- 187 **Supplementary Table 1-3**. Details of normalization, quality control, and imputation of
- the HC and patient samples are also presented in the **Supplementary Methods**.

189 Epigenetic age analysis

190 The index patient, family control, and unrelated HC blood, buccal, and T-cell epigenetic

- age were estimated with the Horvath pan-tissue clock,³⁴ Hannum clock,³⁵ and Horvath
- 192 skin and blood clock³⁶ using the methylclock R package (Supplementary Methods).

193 Differential DNA methylation analysis

194 Cell-type proportion prediction, subsequent accounting for intersample cellular 195 heterogeneity, and adjusting for other sources of batch effects were performed prior to 196 differential methylation analysis as presented in the **Supplementary Methods**. For 197 differential DNA methylation analysis, linear regression were performed with limma.³⁷ 198 For each primary tissue, the regression model accounted for sex and age, whereas for 199 cultured T-cells we additionally accounted for batch and CD8 T-cell proportion 200 measured by flow cytometry. Details of the regression model are presented in the 201 Supplementary Methods. Multiple test correction was performed with the Benjamini-202 Hochberg procedure³⁸. Skewness of the differential DNAm pattern was assessed with 203 skewness test for normality, implemented with skewness.norm.test function in the 204 normtest package.39

205 Enrichment analysis

- 206 Overrepresentation analyses were performed to identify enriched ChromHMM
- 207 chromatin states with the *gometh* function in the missMethyl package
- 208 (Supplementary Methods).
- 209 Intracellular flow cytometry in PBMCs, expanded T-cells, and primary fibroblasts

- 210 Intracellular flow cytometry was performed to examine the expression of ASXL1,
- 211 H2AK119ub1, and IL-2-induced phosopho-STAT5 (pSTAT5) in expanded patient-
- 212 derived primary T-cells; pSTAT5 in PBMCs; and ASXL1 in primary fibroblasts
- 213 (Supplementary Methods).

214 Clinical-grade flow cytometry

- 215 Immunophenotyping of clinical samples was performed using WB at an accredited
- 216 clinical flow cytometry laboratory following established standard protocols
- 217 (Supplementary Methods).

218 Histology

- 219 Formalin-fixed, paraffin-embedded lymph node tissue was cut into sections 3 µm thick
- 220 for routine hematoxylin and eosin (H&E) staining or 5 μ m thick for
- 221 immunohistochemistry. Bone marrow trephine biopsies were processed in B-plus
- solution followed by decalcification and formalin fixation. Paraffin embedded marrow
- tissue was then cut into sections 3 µm thick for routine hematoxylin and eosin (H&E)
- staining or 4 µm thick for immunohistochemistry.

225 Data availability

226 The data is available upon request by emailing the corresponding author.

227 **RESULTS**

228 Case description

229 The index patient is currently an adolescent female (10 to 19 years of age) born to

- 230 nonconsanguineous parents. One parent has a history of rheumatoid arthritis, while the
- 231 other parent and sibling have no notable clinical history. The index patient was born full-
- term and received all routine immunizations, including live attenuated measles, mumps,
- rubella (MMR) vaccine (**Fig. 1A**). During early childhood (0 to 5 years of age), she
- 234 developed chronic ulcerated skin granulomas on the right arm and left leg. She was
- 235 hospitalized twice for pneumonia between 0 to 10 years of age, with the latter in the
- 236 context of primary EBV infection. Laboratory tests over time showed chronic
- 237 macrocytosis, T-cell lymphopenia, progressive loss of B-cells, and
- 238 hypogammaglobulinemia (**Fig. 1B, Supp. Fig. 1B**).
- 239 Despite prolonged systemic courses of antimicrobials, topical corticosteroids and wound
- care, the skin granulomas persisted for more than a decade, with new lesions
- 241 developing in the left inguinal region. Repeated biopsies showed necrotizing
- granulomatous inflammation with no organisms identified on special stains. (Fig. 1C,
- 243 **Supp. Fig. 1C**). Serial bone marrow biopsies every 1–2 years showed mild
- 244 hypocellularity, megaloblastoid changes, and eventually the presence of non-necrotizing
- granulomas (Fig. 1D). Infectious studies revealed intermittent EBV viremia (ranging
- from 0 to 1000s copies/mL), absent antibody titers to measles, mumps, varicella, and
- 247 hepatitis B, but high titers to rubella. A biopsy from one of the cutaneous granulomas
- 248 was tested for vaccine-strain rubella, RA 27/3, and was found to be positive by
- 249 polymerase chain reaction.
- 250 In early adolescence (10 to 15 years of age), the patient was diagnosed with EBV-
- associated stage IVA classical Hodgkin lymphoma, mixed cellularity subtype with
- 252 prominent granulomatous inflammation (Supp Fig 1D and Supplementary Clinical
- **Data)**. She underwent four cycles of chemotherapy, at which time a repeat Positron
- 254 Emission Topography (PET)-CT showed progressive disease, and she was transitioned
- to nivolumab, anti- programmed cell death protein 1 (PD1) antibody, immunotherapy.

- 256 This was complicated by the development of autoimmune thyroiditis treated with
- thyroxine. Six weeks following discontinuation of nivolumab, conditioning was begun for
- a 9/10 matched unrelated donor hematopoietic stem cell transplant (HSCT) with
- 259 cyclophosphamide, fludarabine and 200cGy total body irradiation. She received
- 260 mycophenolate mofetil and tacrolimus prophylaxis for graft versus host disease (GVHD)
- 261 and developed grade 1 GVHD of upper gut and skin which was treated with
- corticosteroids. She was discharged on day +34 with full donor chimerism, and remains
- well now 6 months posttransplant with healing of her chronic skin lesions.

Identification and characterization of novel germline compound heterozygous ASXL1 variants in the index patient

- 266 Given the unique clinical presentation and the severity of the clinical phenotype, trio-
- 267 WES and subsequent WGS were performed. Sequencing results identified compound
- heterozygous variants in ASXL1, a maternally inherited variant in exon 5 (Var1:
- 269 NM_015338.6:c.332G>A;NP_056153.2:p.Cys111Tyr) and a paternally inherited variant
- 270 in exon 13 (Var 2: NM_015338.6:c.3710C>T;NP_056153.2:p.Ser1237Phe), as
- 271 candidates. Sequencing confirmed that the biallelic *ASXL1* variants segregated with the
- 272 presence of disease in the family (Fig. 2A,B). These are missense variants predicted to
- be deleterious, and were considered to be strong candidates for further functional
- evaluation based on their changes in amino acid polarities, high combined annotation-
- dependent depletion (CADD) scores (Var1: 26.2; Var 2: 23.0), and their low allelic
- 276 frequency in the Genome Aggregation Database (gnomAD) v3 (Var1: 8.12e-06; Var2:
- 1.22e-05, with no homozygotes for either variant; **Supp. Fig. 2A**). Both variants fell
- 278 outside the mutation hotspot region associated with typical truncating BOS variants in
- 279 ASXL1 exon 13 (**Fig. 2C**).
- 280 Molecular consequences of the patient's *ASXL1* variants were investigated next.
- 281 Expanded patient primary T-cells (both CD4 and CD8) expressed approximately half the
- amount of total ASXL1 protein when compared to both healthy controls (HCs) and
- family members (p<0.05, Fig 2D). ASXL1 deficiency was also confirmed in patient
- cultured fibroblasts obtained from a skin biopsy (Fig. 2E). Given the well-described role

- of ASXL1 in H2AK119 deubiquitination,⁴⁰ we quantified H2AK119ub1 in expanded T-
- cells but did not find notable differences in bulk enrichment levels between the patient
- and controls (Fig. 2F). While surprising, recent work has shown that BOS-causing
- 288 germline ASXL1 variants do not alter specific histone modifications, including
- H2AK119ub1, but rather cause DNAm dysregulation.²³ Therefore, we next assessed the
- 290 global DNAm signatures in the patient.

Differential DNAm in PRC-regulated genomic elements and advanced epigenetic aging in the patient's lymphocytes

- 293 We conducted epigenome-wide association studies (EWAS) to compare the DNAm
- 294 patterns of primary patient samples to age-matched HCs compiled from publicly
- available data sets in three tissue types: buccal swabs (n = 725), whole blood (WB) (n =
- 452), and isolated PBMCs (n = 285). We observed wide-spread differential DNAm
- between the patient and HCs in WB and PBMCs (Fig. 3A) but not in buccal swabs
- 298 (Supp. Fig. 3A). There were 50 885 differentially methylated sites (DMs) in WB, 18 581
- 299 DMs in PBMCs, but only 38 DMs in buccal swabs that passed the threshold of adjusted
- 300 *P*-value (P_{adj}) \leq .05, 15.7% of which (9438 DMs) overlapped between WB and PBMCs
- 301 (Fig. 3B). Emphasizing that this patient does not have BOS, we found that BOS-
- associated DMs were not enriched in our analysis (**Supp. Fig. 3B**). Pathway enrichment
- analysis with 18-state ChromHMM chromatin state annotation showed that DMs in both
- 304 WB and PBMCs were significantly enriched in regulatory elements, such as enhancers,
- 305 bivalent transcription start sites, and repressed Polycomb regions, as well as some
- 306 quiescent gene and heterochromatin regions in PBMCs (**Fig. 3C**).
- 307 To gain further information about the patient's DNA methylome, we assessed the
- 308 patient's tissue-specific EA. In analysis of buccal swabs, the patient was estimated to
- 309 have a pediatric buccal epigenetic (PedBE) clock age of 10 to 15 years, matching her
- actual age of 10 to 15 years at sample collection (**Supp. Fig. 3C**). In contrast, the
- 311 Horvath pan-tissue age of blood samples was higher compared to her chronological age
- 312 (Fig. 3D). Similarly, the predicted telomere length based on DNAm data was also lower
- in blood (**Fig. 3D**), and the presence of short telomeres in lymphocytes and

- 314 granulocytes was confirmed by direct measurement (Supp. Fig. 3D). Overall, the
- 315 ASXL1-deficient patient had increased EA and short telomeres compared to HC, which
- 316 was especially prominent in lymphocyte subsets.

317 Wide-spread DNAm loss and advanced epigenetic aging in patient's T-cells were 318 rescued by WT *ASXL1* transduction

- 319 We transduced expanded patient-derived T-cells with WT ASXL1 to delineate the 320 relations between the patient's variants and the alterations in epigenetic regulation in 321 lymphocytes. Whereas empty vector (EV)-transduced patient cells (patient condition) 322 maintained a lower ASXL1 protein level compared to the EV-transduced HC cells (HC 323 condition), WT ASXL1-transduced patient cells (rescued condition) showed increased 324 ASXL1 protein comparable to the HC condition (Fig. 4A). 325 Principal component analysis (PCA) of the T-cells' DNAm showed that the patient 326 clustered away from the HC (including family member) cells along PC2, with the 327 rescued cells in the middle (Fig. 4B). Analysis of the *patient vs. HC* comparison yielded 328 141 113 differentially methylated sites (DMs) ($P_{adj} < .2$ and delta-beta > 0.1), of which 329 129,104 (91.5%) showed decreased DNAm. The pattern observed in the PCA plot was 330 replicated in the DMs-patient samples were notable for their decreased DNAm, while 331 the rescued condition showed an intermediate DNAm level (Fig. 4C). Furthermore, loss 332 of DNAm in the patient condition occurred mainly in loci that were highly methylated in 333 HC samples; of the DMs with decreased DNAm, 80.1% were > 50% methylated in the 334 HCs (skewness test P < 2.2e-16, Fig. 4C). In the rescued vs. HC condition, 35 457 335 DMs were identified, and 90 354 of the *patient vs. HC* DMs were not significantly 336 different in this comparison, indicating that the majority of the DMs in the patient's cells 337 were rescued by WT ASXL1 transduction (Fig. 4D). Similar to our findings in blood, the 338 genomic locations of DMs were highly enriched for repressed Polycomb and bivalent 339 chromatin states, with the rescued cells showing higher *P*-values than that of patient 340 cells (Fig. 4D,E).
- 341 We also investigated epigenetic aging in this context. For the controls, the Horvath pan-342 tissue clock slightly underpredicted chronological age. In contrast, the clock assigned

- 343 the patient an epigenetic age on average 27.4 years older than her chronological age,
- and WT ASXL1 lowered her epigenetic age (Fig. 4F). Specifically, the difference
- 345 between epigenetic and chronological age was significantly higher in the patient than
- family and unrelated HCs, and this difference was significantly reduced by WT ASXL1
- (P < .0005) (Fig. 4F). Other epigenetic clocks corroborated the trend (Supp. Fig. 4A,B).
- 348 Overall, WT ASXL1 transduction rescued the DNAm differences and attenuated the
- advanced epigenetic aging driven by the patient's *ASXL1* variants.

ASXL1 variants caused impaired CD4 and CD8 T-cell maintenance and activation in patient primary cells

352 Given the methylation impairments in patient T-cells, we conducted detailed 353 immunophenotyping of peripheral blood prior to the patient's lymphoma diagnosis. 354 Naïve CD4 and CD8 T-cell subsets and recent thymic emigrants were markedly 355 reduced, suggesting poor thymic output (Fig. 5A, Table 1). The patient showed 356 expansion of PD1⁺ CD4 and CD8, and CD57⁺ CD8 T-cell populations (Fig. 5A), 357 indicating T-cell exhaustion and senescence. CD8 T-cells had a restricted T-cell 358 receptor repertoire (**Table 1**). We then assessed pSTAT5 signaling and reactive oxygen 359 species (ROS) production, as alterations in these pathways were reported in T-cells 360 containing an ASXL1 variant associated with clonal hematopoiesis of indeterminate potential.²⁹ We observed significantly increased pSTAT5 abundance after low-dose IL-2 361 362 (10U/mL) treatment in naïve CD8 T-cells (Fig 5B) but no difference in the memory T-363 cell compartment (Supp Fig 5A-B). Reduced pSTAT5 production was observed in expanded patient CD8 T-cells after IL-2 treatment, which was rescued by stable WT 364 365 ASXL1 expression, indicating a causative role for ASXL1 in regulating STAT5-mediated 366 CD8 T-cell homeostasis (Fig 5C). Finally, high ROS production was observed in 367 expanded patient CD4 T-cells, which was rescued upon transduction of WT ASXL1 368 (Supp Fig 5C), suggesting alternative modes of ASXL1 variant-mediated impairments 369 of CD4 and CD8 T-cells.

Fu, Sharma et al.

370 DISCUSSION

371 Here, we reported the clinical, epigenetic, and biochemical findings of the first case of 372 autosomal recessive ASXL1 deficiency in a female with combined immunodeficiency 373 and EBV-associated Hodgkin lymphoma. Single-patient studies account for 374 approximately one-third of newly identified monogenic immune disorders,¹ requiring 375 methodical validation to establish causality. Following the guidelines proposed by Casanova et al. for studies in single patients,⁴¹ we showed that the ASXL1 variants 376 377 identified in the patient are rare, monogenic, and have complete penetrance. Studies in 378 primary patient cells demonstrated decreased ASXL1 protein levels, dysregulated 379 DNAm, and epigenetic age acceleration. Finally, we showed that epigenetic and 380 immunological defects in the patient's cells were rescued by transduction of WT ASXL1. 381 The patient's rare and severe clinical presentation provided further support for an 382 underlying genetic cause.⁴¹ She had a combined immunodeficiency, with T-cell 383 lymphopenia from early childhood followed by progressive loss of B-cells. After 384 receiving live MMR vaccine, she developed vaccine-strain rubella-positive granulomas. 385

From a hematology/oncology perspective, she had persistent macrocytosis and mild
bone marrow hypocellularity, and developed chemorefractory advanced Hodgkin
lymphoma. Based on our findings, patients presenting with this unique clinical profile
should be evaluated for autosomal recessive ASXL1 deficiency.

390 Epigenome-wide association studies (EWAS) showed significant alterations of DNAm in

391 patient T-cells, PBMCs, and WB, but not buccal swabs; DNAm decreased

392 predominately in T-cells and WB, but was increased in PBMCs. The contrasting

393 significance and directionality of EWAS results across tissue types suggests cell type-

394 specific impacts of the *ASXL1* variants on global DNAm. This was further supported by

the observation of pronounced increase in epigenetic age and reduced telomere length

396 exclusively in lymphocytes. Global hypomethylation and focal hypermethylation are key

397 features of aging, as epigenetic marks are ineffectively maintained through S phase of

398 mitosis.⁴² We showed the patient's *ASXL1* LoF variants drive epigenetic features with

399 DNAm loss and increased epigenetic age in T-cells. This is supported by recent findings

showing altered chromatin accessibility and DNAm inhibition in *ASXL1* KO CD8 T cells⁴³, and high epigenetic age differences in BOS patients with *ASXL1* truncation

402 variants²⁴, highlighting the role of *ASXL1* on cellular aging.

403 Our detailed molecular and clinical evaluation of human ASXL1 deficiency provides 404 further insight into the role of immune dysregulation in cancer predisposition. Global 405 hypomethylation has also been proposed to act as a replicative barrier against highly proliferative and premalignant cells by inducing cellular senescence.^{44,45} In this case. 406 407 however, T-cell senescence may have played a role in impaired antiviral and antitumor 408 immunity, contributing to the development of EBV-associated Hodgkin lymphoma.⁴⁶ 409 Indeed, recent modeling of an ASXL1 variant associated with clonal hematopoiesis 410 showed that it promoted the progression of solid tumors via impaired intrathymic T-cell development, naïve-memory T-cell imbalance, and T-cell exhaustion²⁹. Loss of Asx/1 411 412 and overexpression of truncated Asxl1 in mice also lead to limited hematopoietic stem cell self-renewal capacity and decreased peripheral lymphocyte numbers.^{22,29,47,48} 413 414 Consistent with these findings, we also observed the near-absence of recent thymic 415 emigrants and naïve T-cells, combined with T-cell exhaustion in the patient. The altered 416 epigenetic and immune landscape, advanced cellular aging, CD8 T-cell senescence, 417 and T-cell exhaustion in the context of chronic infection likely all contribute to an 418 oncogenic environment. Some of these mechanisms may also play roles in other 419 hematopoietic malignancies, specifically acute myeloid leukemia, chronic myelomonocytic leukemia, and MDS,^{49,50,51} where somatic ASXL1 variants are 420 commonly described.⁴⁹ Taken together, ASXL1 LoF variants may drive the maintenance 421 422 of a protumor milieu.

The granulomas that emerged in early childhood (0 to 5 years of age) represented a particularly enigmatic feature of this patient's clinical course. These lesions persisted for more than a decade, were refractory to treatment, and were labeled as idiopathic until recognized as positive for vaccine-strain rubella virus. Rubella virus was first identified in the granulomas of three IEI patients in 2014,⁵² and are now linked to ~60% of idiopathic cutaneous granulomas in IEIs. Rubella granulomas have been typically found

in individuals with ataxia telangiectasia and other related DNA repair disorders.^{53,54,55,56}
Our study adds to this relatively new field by suggesting dysregulation of an epigenetic
modifier, *ASXL1*, as a cause of vaccine-strain rubella-associated granuloma. The
profound T-cell impairments and deficiency described here represent possible
underlying mechanisms, as defective T-cell cytotoxicity has been implicated in rubella
vaccine-associated granulomas.⁵⁶ Further studies are needed to elucidate the
immunological basis of this rare and serious complication.⁵⁶

436 Heterozygous germline truncating variants of ASXL1 are known to cause the neurodevelopmental disorder BOS.⁵⁷ The hematologic and immune disorder described 437 438 here was distinct from BOS in both its molecular and clinical effects. We identified 439 biallelic missense ASXL1 variants located outside the mutational hotspot associated 440 with BOS. The DNAm signature in our patient also does not overlap with that seen in BOS patients²⁴. A recent study further showed no impairment of ASXL1 protein level in 441 BOS patients, contrasting our findings.²³ Studies in mouse models indicated that 442 443 Asx/1^{-/-} mice show developmental abnormalities and failure to thrive, recapitulating elements of the BOS patient phenotype,^{22,47} while Asx/1^{-/+} mice develop an MDS-like 444 phenotype possibly attributable to Asx/1 haploinsufficiency.²² Given these findings, 445 446 BOS-causing ASXL1 variants likely have different functional impacts than those in our 447 patient, which may contribute to the distinct phenotype observed. Future studies directly 448 comparing samples from patients with autosomal recessive ASXL1 deficiency to those 449 with BOS may further elucidate the mechanistic differences between these two 450 diseases.

This study had many strengths, notably the detailed clinical and immunological
description of the first human case of biallelic ASXL1 deficiency and well-controlled
epigenetic profiling with family controls and a population reference data set across
multiple tissues. However, there were also limitations. First, this was a single-patient
study, and ultimately the full phenotype of human ASXL1 deficiency will only be defined
through diagnosis of more patients. Second, while we observed global differential
DNAm in patient whole blood and PBMCs, we explored the effect of WT ASXL1

transduction only in patient T-cells. Sample limitations restricted us from working on
other cell types (eg, neutrophils) in a controlled setting. Similar to previous findings, we
showed the effects of *ASXL1* variants to be highly cell type-specific,⁴⁸ and therefore
examining different cellular models could elucidate the roles of ASXL1 in hematopoiesis
and disease. Finally, although our patient has benefitted clinically from allogeneic
HSCT, follow-up was only 6 months at the time of writing, so the observed benefits
should be interpreted with caution.

465

466 In conclusion, our study identified a novel human IEI caused by germline biallelic

467 deleterious ASXL1 variants. These observations will empower diagnosis of future

468 patients with ASXL1 deficiency, and expand the clinical spectrum of disease associated

469 with LoF *ASXL1*. We recommend genetic testing at the first sign of combined immune

470 deficiency as a powerful precision medicine approach to guide diagnosis and inform

471 therapeutic decision-making processes.

Acknowledgements: We are grateful to our colleagues, Karlie Edwards, Chaini Konwar, Hilary Brewis, Hannah-Ruth Engelbrecht, and Alan Kerr, who critically contributed to the flow and style of the manuscript. Thanks are also due to Nicole Gladish who facilitated the downloading and merging of ChromHMM data from the Roadmap Epigenomics database. We are also grateful for the help in patient management and organization of the investigation effort we received from Anne K Junker.

- Funding: This work was supported by grants from the Canadian Institutes of Health
 Research (EGM-141897) (M.S.K.) (PJT-178054) (S.E.T., C.M.B.), Genome British
 Columbia (SIP007) (S.E.T.), Michael Smith Health Research BC (HPI-2018-2014)
 (C.M.B.) and BC Children's Hospital Foundation. M.S.K. is the Edwin S.H. Leong UBC
 Chair in Healthy Aging, C.M.B. is a MSHRBC Health Professional-Investigator, and S.E.T.
 holds a Tier 1 Canada Research Chair in Pediatric Precision Health and the Aubrey J.
 Tingle Professor of Pediatric Immunology.
- 485 **Contribution:** Contribution described using the CRediT taxonomy.
- 486 Contributions=Conceptualization, Methodology, Formal Analysis, Investigation,
- 487 Visualization, Writing-original draft preparation, Writing-reviewing and editing (Maggie P
- 488 Fu, Mehul Sharma).
- 489 Contributions= Investigation, Resources, Writing-reviewing and editing (Sarah Merrill,
- 490 Pariya Yousefi, Ryan Tan, Bhavi P Modi, Kate Del Bel, Rebecca J Deyell, Jacob
- 491 Rozmus, Wingfield Rehmus, Kyla J Hildebrand, Elliot James, Géraldine Blanchard-
- 492 Rohner, Susan Lin, Kevin E Shopsowitz, Audi Setiadi, Jefferson Terry, Anna F Lee, Britt
- 493 I Drögemöller, Allison Matthews, Maja Tarailo-Graovac, Laura Sauvé, Hana Mitchell,
- 494 Julie S Prendiville, Julie L MacIsaac, Kristy Dever, David T S Lin, Mandy Meijer, Colin J
- 495 D Ross, Simon R M Dobson, Suzanne M Vercauteren, Wyeth W Wasserman, Clara D
- 496 M van Karnebeek, Margaret L McKinnon).
- 497 Contributions=Conceptualization, Methodology, Investigation, Validation, Visualization,
- 498 Resources, Funding acquisition, Project administration, Supervision, Writing-original

- 499 draft preparation, Writing-reviewing and editing (Michael S Kobor, Stuart E. Turvey,
- 500 Catherine M Biggs).
- 501 **Conflict of Interest Disclosures:** The authors report no conflicts of interest in relation 502 to this manuscript.

503 **REFERENCES**

- 1. Tangye SG, Al-Herz W, Bousfiha A, et al. Human inborn errors of immunity: 2022
- 505 update on the classification from the International Union of Immunological Societies 506 Expert Committee. *J. Clin. Immunol.* 2022;42(7):1473–1507.
- 507 2. Romano R, Cillo F, Moracas C, et al. Epigenetic alterations in inborn errors of 508 immunity. *J. Clin. Med.* 2022;11(5):.
- 509 3. Fu MP, Merrill SM, Sharma M, et al. Rare diseases of epigenetic origin: Challenges 510 and opportunities. *Front. Genet.* 2023;14:1113086.
- 4. Izzo F, Lee SC, Poran A, et al. DNA methylation disruption reshapes the
- 512 hematopoietic differentiation landscape. *Nat. Genet.* 2020;52(4):378–387.
- 513 5. Campos-Sanchez E, Martinez-Cano J, Del Pino Molina L, Lopez-Granados E,
- 514 Cobaleda C. Epigenetic deregulation in human primary immunodeficiencies. *Trends* 515 *Immunol.* 2019;40(1):49–65.
- 516 6. Haas OA. Primary immunodeficiency and cancer predisposition revisited: embedding
- 517 two closely related concepts into an integrative conceptual framework. *Front. Immunol.* 518 2018;9:3136.
- 519 7. Stremenova Spegarova J, Lawless D, Mohamad SMB, et al. Germline TET2 loss of
- 520 function causes childhood immunodeficiency and lymphoma. *Blood*. 2020;136(9):1055– 521 1066.
- 522 8. Tiri A, Masetti R, Conti F, et al. Inborn errors of immunity and cancer. *Biology*. 523 2021;10(4):.
- 524 9. Hauck F, Voss R, Urban C, Seidel MG. Intrinsic and extrinsic causes of malignancies
- 525 in patients with primary immunodeficiency disorders. J. Allergy Clin. Immunol.
- 526 2018;141(1):59-68.e4.
- 527 10. Leeksma OC, de Miranda NF, Veelken H. Germline mutations predisposing to diffuse large B-cell lymphoma. *Blood Cancer J.* 2017;7(2):e532.
- 529 11. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis
- associated with adverse outcomes. *N. Engl. J. Med.* 2014;371(26):2488–98.
- 531 12. Genovese G, Kahler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-
- 532 cancer risk inferred from blood DNA sequence. *N. Engl. J. Med.* 2014;371(26):2477–87.
- 533 13. Zink F, Stacey SN, Norddahl GL, et al. Clonal hematopoiesis, with and without
- 534 candidate driver mutations, is common in the elderly. *Blood*. 2017;130(6):742–752.
- 535 14. Shlush LI. Age-related clonal hematopoiesis. *Blood*. 2018;131(5):496–504.
- 536 15. Kassis JA, Kennison JA, Tamkun JW. Polycomb and trithorax group genes in *Drosophila. Genetics.* 2017;206(4):1699–1725.
- 538 16. Li R, Huang D, Zhao Y, et al. PR-DUB safeguards Polycomb repression through 539 H2AK119ub1 restriction. *Cell Prolif.* 2023;
- 540 17. Macrae TA, Fothergill-Robinson J, Ramalho-Santos M. Regulation, functions and
- 541 transmission of bivalent chromatin during mammalian development. *Nat. Rev. Mol. Cell* 542 *Biol.* 2023;24(1):6–26.
- 543 18. Kasinath V, Beck C, Sauer P, et al. JARID2 and AEBP2 regulate PRC2 in the
- 544 presence of H2AK119ub1 and other histone modifications. *Science*.
- 545 2021;371(6527):eabc3393.

- 546 19. Bonnet J, Boichenko I, Kalb R, et al. PR-DUB preserves Polycomb repression by
- 547 preventing excessive accumulation of H2Aub1, an antagonist of chromatin compaction. 548 *Genes Dev.* 2022;36(19–20):1046–1061.
- 549 20. Bedoukian E, Copenheaver D, Bale S, Deardorff M. Bohring-Opitz syndrome
- 550 caused by an ASXL1 mutation inherited from a germline mosaic mother. *Am. J. Med.*
- 551 Genet. A. 2018;176(5):1249–1252.
- 552 21. Abdel-Wahab O, Gao J, Adli M, et al. Deletion of Asxl1 results in myelodysplasia
- and severe developmental defects in vivo. J. Exp. Med. 2013;210(12):2641–2659.
- 554 22. Wang J, Li Z, He Y, et al. Loss of AsxI1 leads to myelodysplastic syndrome-like 555 disease in mice. *Blood*. 2014;123(4):541–553.
- 556 23. Lin I, Wei A, Awamleh Z, et al. Multiomics of Bohring-Opitz syndrome truncating
- 557 ASXL1 mutations identify canonical and noncanonical Wnt signaling dysregulation. *JCI* 558 *Insight*. 2023;8(10):.
- 559 24. Awamleh Z, Chater-Diehl E, Choufani S, et al. DNA methylation signature
- associated with Bohring-Opitz syndrome: a new tool for functional classification of
- 561 variants in ASXL genes. *Eur. J. Hum. Genet.* 2022;30(6):695–702.
- 562 25. Nischal S, Bhattacharyya S, Christopeit M, et al. Methylome profiling reveals distinct
- alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms.
 Cancer Res. 2013;73(3):1076–85.
- 565 26. Rahmani NE, Ramachandra N, Sahu S, et al. ASXL1 mutations are associated with
- distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine. *Blood Cancer J.* 2021;11(9):157.
- 568 27. Shi H, Yamamoto S, Sheng M, et al. ASXL1 plays an important role in 569 erythropoiesis. *Sci. Rep.* 2016;6:.
- 570 28. Fang X, Xu S, Zhang Y, et al. Asxl1 C-terminal mutation perturbs neutrophil
- 571 differentiation in zebrafish. *Leukemia*. 2021;35(8):2299–2310.
- 572 29. Liu X, Sato N, Shimosato Y, et al. CHIP-associated mutant ASXL1 in blood cells 573 promotes solid tumor progression. *Cancer Sci.* 2022;113(4):1182–1194.
- 574 30. Tarailo-Graovac M, Shyr C, Ross CJ, et al. Exome sequencing and the
- 575 management of neurometabolic disorders. *N. Engl. J. Med.* 2016:374(23):2246–55.
- 576 31. van Kuilenburg ABP, Tarailo-Graovac M, Richmond PA, et al. Glutaminase
- 577 deficiency caused by short tandem repeat expansion in GLS. N. Engl. J. Med.
- 578 2019;380(15):1433–1441.
- 579 32. Kutner RH, Zhang XY, Reiser J. Production, concentration and titration of
- 580 pseudotyped HIV-1-based lentiviral vectors. *Nat. Protoc.* 2009;4(4):495–505.
- 581 33. Sharma M, Fu MP, Lu HY, et al. Human complete NFAT1 deficiency causes a triad
- of joint contractures, osteochondromas, and B cell malignancy. *Blood.* 2022;
- 583 34. Horvath S. DNA methylation age of human tissues and cell types. *Genome Biol.* 2013;14(10):.
- 585 35. Hannum G, Guinney J, Zhao L, et al. Genome-wide methylation profiles reveal
- 586 quantitative views of human aging rates. *Mol. Cell.* 2013;49(2):359–367.
- 587 36. Horvath S, Oshima J, Martin GM, et al. Epigenetic clock for skin and blood cells
- 588 applied to Hutchinson Gilford Progeria Syndrome and ex vivo studies. *Aging*.
- 589 2018;10(7):1758–1775.

- 590 37. Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses
- for RNA-sequencing and microarray studies. *Nucleic Acids Res.* 2015;43(7):e47.
- 592 38. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and 593 powerful approach to multiple testing. *J. R. Stat. Soc. series B (Methodological).*
- 594 1995;57(1):289-300.
- 595 39. Shapiro SS, Wilk MB, Chen HJ. A comparative study of various tests for normality. 596 JASA. 1968;63(324):1343-72.
- 597 40. Scheuermann JC, de Ayala Alonso AG, Oktaba K, et al. Histone H2A deubiquitinase 598 activity of the Polycomb repressive complex PR-DUB. *Nature*. 2010;465(7295):243–7.
- 599 41. Casanova JL, Conley ME, Seligman SJ, Abel L, Notarangelo LD. Guidelines for
- genetic studies in single patients: lessons from primary immunodeficiencies. *J. Exp. Med.* 2014;211(11):2137–49.
- 42. Sen P, Shah PP, Nativio R, Berger SL. Epigenetic mechanisms of longevity and aging. *Cell.* 2016;166(4):822–839.
- 43. Kang TG, Lan X, Alli S, O'Connell CL et al. ASXL1 disruption preserves CD8 T cell
- exhaustion-progenitor epigenetic programming during chronic stimulation. *J. Immun.* 2023;210(1_Supplement):226-10.
- 607 44. Cruickshanks HA, McBryan T, Nelson DM, et al. Senescent cells harbour features of 608 the cancer epigenome. *Nat. Cell Biol.* 2013;15(12):1495–506.
- 45. Johnstone SE, Gladyshev VN, Aryee MJ, Bernstein BE. Epigenetic clocks, aging,
- 610 and cancer. *Science*. 2022;378(6626):1276–1277.
- 46. Zhao Y, Shao Q, Peng G. Exhaustion and senescence: two crucial dysfunctional
- 612 states of T cells in the tumor microenvironment. *Cell. Mol. Immunol.* 2020;17(1):27–35.
- 47. Abdel-Wahab O, Gao J, Adli M, et al. Deletion of Asxl1 results in myelodysplasia
- and severe developmental defects in vivo. J. Exp. Med. 2013;210(12):2641–2659.
- 48. Nagase R, Inoue D, Pastore A, et al. Expression of mutant Asxl1 perturbs
- 616 hematopoiesis and promotes susceptibility to leukemic transformation. J. Exp. Med.
- 617 2018;215(6):1729–1747.
- 49. Micol J-B, Abdel-Wahab O. The role of Additional sex combs-like proteins in cancer.
 619 Cold Spring Harb. Perspect. Med. 2016;6(10):a026526.
- 620 50. Boultwood J, Perry J, Pellagatti A, et al. Frequent mutation of the polycomb-
- 621 associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid 622 leukemia. *Leukemia*. 2010;24(5):1062–5.
- 51. Russell B, Graham, J. M. Jr. Expanding our knowledge of conditions associated with
- 624 the ASXL gene family. *Genome Med.* 2013;5(2):16.
- 52. Bodemer C, Sauvage V, Mahlaoui N, et al. Live rubella virus vaccine long-term
- 626 persistence as an antigenic trigger of cutaneous granulomas in patients with primary 627 immunodeficiency. *Clin. Microbiol. Infect.* 2014;20(10):O656-63.
- 628 53. Zhang D, Wanat KA, Perelygina L, et al. Cutaneous granulomas associated with
- 629 rubella virus: a clinical review. J. Am. Acad. Dermatol. 2023;
- 630 54. Buchbinder D, Hauck F, Albert MH, et al. Rubella virus-associated cutaneous
- 631 granulomatous disease: a unique complication in immune-deficient patients, not limited
- 632 to DNA repair disorders. *J. Clin. Immunol.* 2019;39(1):81–89.

- 633 55. Perelygina L, Icenogle J, Sullivan KE. Rubella virus-associated chronic inflammation
- 634 in primary immunodeficiency diseases. *Curr. Opin. Allergy Clin. Immunol.*635 2020;20(6):574–581.
- 2020, 20(0), 374 301.
- 636 56. Gross M, Speckmann C, May A, et al. Rubella vaccine-induced granulomas are a
- novel phenotype with incomplete penetrance of genetic defects in cytotoxicity. *J. Allergy Clin. Immunol.* 2022;149(1):388-399 e4.
- 639 57. Hoischen A, van Bon BWM, Rodríguez-Santiago B, et al. De novo nonsense
- 640 mutations in *ASXL1* cause Bohring-Opitz syndrome. *Nat. Genet.* 2011;43(8):729–731.
- 641

- 642 Table 1: Immunophenotyping of Index patient lymphocytes in early adolescence
- 643 (10-15 years-of-age). Red denotes high values and blue denotes low values. The *
- 644 indicates values with a reference range that is based on adult healthy controls.

Hematologic and immunologic parameters	Index Patient	Age matched Reference range
T-cell subsets (Units)		
CD3⁺ (10 ⁹ cells/L)	0.374	0.850-3.200
CD3 ⁺ CD4 ⁺ (10 ⁹ cells/L)	0.151	0.400-2.100
CD3⁺CD8⁺ (10 ⁹ cells/L)	0.208	0.300-1.300
CD3 ⁺ CD4 ⁺ CD45RA ⁺ CD31 ⁺ (recent thymic emigrants) (%)	2	31-81
CD3+4+45RA+27+ (naïve) (%)	30	37-97
CD3+4+45RA+27- (terminally differentiated) (%)	0.588	0.004-5.800
CD3+4+45RA ⁻ 27 ⁻ (effector memory) (%)	8.922	0.490-25
CD3+4+45RA ⁻ 27+ (central memory) (%)	61	13-76
CD4 ⁺ PD1 ⁺ (%)*	60.6	3.2 - 20.4
CD4 ⁺ CD57 ⁺ (%) [*]	2.8	0.3 - 13.9
CD3+8+45RA+197+27+ (naïve) (%)	1	20-95
CD3+8+45RA+197-27- (terminally differentiated) (%)	60	9-65
Cd3 ⁺ 8 ⁺ 45RA ⁻ 197 ⁻ 27 ⁻ (effector memory) (%)	0	4-100
CD3+8+45RA-197+27+ (central memory) (%)	8.00	0.42-18
CD8+PD1+ (%)*	63.3	4.7 – 40.7
CD8+CD57+ (%)*	64.0	4.1 – 51.9
B-cell subsets (Units)		
	0.069	0.120-0.740
CD19 ⁺ B lymphocyte absolute (10 [°] cells/L) CD19 ⁺ CD27 ⁺ memory B-cells (%)	1.3	13.3-47.9
CD19*CD27 ⁻ IgD⁺ naïve (%)	86.1	57.3-82.5
CD19*CD27*IgM*IgD*CD38 ^{dim} CD24* (memory, non-switched) (%)	0.8	4.6-18.2
CD19⁺CD27⁺IgM⁻IgD⁻CD38 ^{dim} CD24⁻ (memory, class switched) (%)	0.5	8.7-25.6
CD19 ⁺ IgM ⁺ CD38 ⁺⁺ (transitional) (%)	0.2	1.4-13.0
CD19⁺CD21 ¹ °CD38 ¹ ° (%)	65	1.0-11.0
Other immunological parameters (Units)		
CD4 ⁺ T-cell repertoire	Normal Polyclonal Pattern	
CD8⁺ T-cell repertoire		
CD3⁺CD8⁺ TCR Vβ12 (% of total CD8 cells)	39.5	0.33-3.33
CD3 ⁺ CD8 ⁺ TCR Vβ14 (% of total CD8 cells)	18.35	1.50-14.30

646 Figure Legends

647 Figure 1: Clinical phenotype of a patient with biallelic ASXL1 variants. A) Clinical 648 timeline depicting the patient's infections requiring hospitalization in early childhood 649 (pneumonia and primary EBV infection with bacterial pneumonia), timing of MMR 650 vaccines, onset of cutaneous granulomas and EBV⁺ Hodgkin lymphoma, and definitive 651 treatment with HSCT. B) Timeline of hematologic parameters, demonstrating 652 normal/elevated hemoglobin, declining platelet and absolute neutrophil counts, chronic 653 macrocytosis, low/normal T-cell counts, and progressive loss of B-cells. C) Image of 654 healing cutaneous granuloma on left knee taken in early adolescence (10-15 years of 655 age). D) Bone marrow biopsy showing mildly hypocellular marrow and presence of a 656 granuloma (arrowhead).

ANC, absolute neutrophil count; Hb, hemoglobin; HSCT, hematopoietic stem cell
transplantation; MCV, mean corpuscular volume; Plt, platelets.

659 Figure 2: Characterization of germline biallelic ASXL1 variants identified in the 660 index patient. A) Family pedigree of ASXL1 variant inheritance pattern. B) Index 661 patient and her family's ASXL1 genotype as verified by sequencing. C) Schematic of 662 major functional domains in ASXL1 and the positions of patient and other reported germline variants. Patient's ASXL1 variants (C111Y and S1237F, labeled red) are 663 664 located outside the mutational hotspot and major functional domains. A variant linked to 665 non-Hodgkin lymphoma (R402Q) is labeled blue, and those linked to BOS are labeled 666 gray. D) Histograms of patient and control ASXL1 protein abundance in expanded T-667 cells (CD4⁺ and CD8⁺) based on flow cytometry, and their respective quantification as 668 measured over four separate experiments. E) Histogram of patient and HC ASXL1 669 protein abundance in cultured fibroblasts using flow cytometry, and their respective 670 quantification as measured over three separate experiments. F) Histogram of patient 671 and HC H2AK119 ubiguitin levels in expanded CD4⁺ and CD8⁺ T-cells based on flow 672 cytometry, and their respective quantification as measured over three separate 673 experiments. Results from one representative experiment are shown in each of D, E,

and F. *P < .05, **P < .01, ***P < .001, one-way analysis of variance and Dunnett's multiple comparison test.

676 Figure 3: Patient and HC DNAm profiles and EA. A) Volcano plot of differential 677 DNAm patterns detected in WB and PBMCs with linear regression. $\Delta\beta$ represents the 678 effect size of the patient status variable after accounting for age at sample collection 679 and sex. Magenta points indicate DMs with increased DNAm in the patient, whereas the 680 turquoise points represent those with decreased DNAm. The vertical dark grav line 681 represents an effect size threshold of 0.1, and the horizontal line corresponds to the 682 statistical threshold of $P_{adj} = .05$. B) Venn diagram showing the overlap of DMs with P_{adj} 683 < .05 in WB and PBMCs. C) Enriched chromatin states based on the DMs in WB and 684 PBMCs using the 18-state ChromHMM model. Overrepresentation analysis was used to 685 extrapolate the significance of the enrichment. The gray dashed line corresponds to Padi 686 = .05. D) Horvath pan-tissue EA was calculated in WB and PBMCs with the methylclock 687 package. HC samples are indicated in light blue, while patient samples are shown in 688 red. The black line is the linear model best fit line. The gray area corresponds to the 689 95% confidence interval.

690 Figure 4: DNA methylation disturbance in expanded patient-derived T-cells and 691 molecular rescue by WT ASXL1 transduction. A) GFP signal and ASXL1 protein 692 abundance in expanded T-cells transduced with either EV or WT ASXL1, as detected 693 by flow cytometry. The vectors contained a GFP tag, so the transduction efficiency was 694 represented by the GFP signal. The HC condition consisted of expanded HC T-cells 695 with EV transduction, while the patient and rescue conditions consisted of expanded 696 patient-derived T-cells transduced with EV or WT ASXL1, respectively. B) Biplot of PC1 697 and PC2 generated by PCA of DNAm measured at all loci on the methylation 698 microarray. Unrelated HC samples are labeled blue, family HCs are labeled orange, 699 patient samples are labeled purple, and rescued samples are labeled green. C) Heat 700 map of DMs in linear regression analysis comparing patient with unrelated and family 701 HC samples, with the DMs in rows and samples in columns. The heat map on the left is 702 row normalized, and that on the right shows the DNAm level (beta value). D) Venn

- 703 diagram showing the DMs in the *patient vs. HC* (purple) and *rescued vs. HC* (green)
- comparisons. The DMs were detected with thresholds of P_{adj} < .2 and delta-beta > 0.1.
- E) Enriched chromatin states based on the DMs in the patient vs. HC (purple) and
- rescued vs. HC (green) comparisons using the 18-state ChromHMM model.
- 707 Overrepresentation analysis was used to extrapolate the significance of the enrichment.
- The gray dashed line corresponds to $P_{adj} = .05$. F) Bar graph showing the differences in
- 709 Horvath pantissue epigenetic age and chronological age of the expanded T-cells. **P* <
- 710 .05, **P < .01, ***P < .001, one-way analysis of variance with Dunnett's multiple
- 711 comparison test.
- 712 GFP, green fluorescent protein; Iso ctrl, isotype control

713 Figure 5: T-cell phenotyping of the index patient. A) T-cell flow cytometry dot plots 714 showing CD4 T and CD8 T-cell-specific comparisons of the patient and one 715 representative age-matched HC. Subset analyses of naïve, TCM, TEM, and TEMRA 716 are shown in the first column, as determined by their expression of CCR7 and CD45RA. 717 Expression levels of the T-cell exhaustion marker PD1⁺ and senescence marker CD57⁺ 718 are presented in columns 2 and 3, respectively, for both CD4 and CD8 T-cells along 719 with the expression of CD45RA. Age-matched reference ranges for quantification of 720 different subsets are presented in Table 1. B) pSTAT5 response in the naïve CD4 T and 721 naïve CD8 T-cell subsets of PBMCs from the patient (purple), family HC (orange), and 722 unrelated HC (light blue) after stimulation with 1, 10, or 100 U/mL IL-2. Flow cytometry 723 histograms of different IL-2 doses are presented on the left. pSTAT5+ cells were 724 guantified by gating after unstimulated HCs. Two different time points of patient samples 725 are represented with different symbols: triangles (time point 1) and circles (time point 2). 726 **P < .01, unpaired t test at each dose followed by the Holm– Šídák multiple comparison 727 test. C) pSTAT5 abundance in expanded T-cells from the patient and controls (HC and 728 family) was measured by flow cytometry with gating for CD4 and CD8 T-cell subsets. 729 Abundance was measured before and after stimulation with 1 U/mL IL-2 for 15 minutes 730 (n = 3). A histogram from one representative experiment is shown here. pSTAT5⁺ cells 731 were determined by gating at the unstimulated patient sample in each experiment. *P <

- 732 .05, **P < .01, ***P < .001, unpaired *t* test at each dose followed by the Holm– Šídák
- 733 multiple comparison test.
- FMO, fluorescence minus one; TCM, central memory T-cell; TEM, effector memory T-
- 735 cell; TEMRA, effector memory RA⁺ T-cell.

Figure 1






Figure 2






Age (years)

Age (years)

Figure 4



Rescued

Family

4

Patient

Figure 5

